5 completed. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 4 | Completed 4 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of GC101 TIL in Advanced Solid Tumors TIL therapy - Tumor Infiltrating Lymphocytes, Safety | Phase 1 | Completed | Shanghai Juncell Therapeutics | 43 | 2022-10-12 | 2025-12-10 |
| Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG Part A) Healthy subjects, Part B) Advanced solid tumor - Immunotherapy | Phase 1 / Phase 2 | Completed | Ajou University School of Medicine | 24 | 2018-11-06 | 2021-07-06 |
| The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy Anlotinib in combination with Immune checkpoint inhibitors - NSCLC, Angiogenesis | Phase 1 / Phase 2 | Completed | The Affiliated Hospital of Qingdao University | 30 | 2018-06-01 | 2020-12-17 |
| ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma Nivolumab, Ipilimumab - Immunotherapy, Head and Neck Neoplasms | Phase 1 / Phase 2 | Completed | The Netherlands Cancer Institute | 33 | 2017-02-28 | 2023-10-23 |
| Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones autologous Melan-A/MART-1 specific CTL clones - Immunotherapy | Phase 1 / Phase 2 | Completed | Nantes University Hospital | 16 | 2000-11-01 | 2008-07-24 |
Drug-Related Side Effects and Adverse Reactions (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Neoplasms (1)
Neoplasms (2) · Neoplasms by Site (2) · Chemically-Induced Disorders (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Skin Diseases (1) · Skin Neoplasms (1) · Skin and Connective Tissue Diseases (1)
Immune Checkpoint Inhibitors (1) · Ipilimumab (1) · Nivolumab (1) · anlotinib (1)
Ajou University School of Medicine (1) · Nantes University Hospital (1) · Shanghai Juncell Therapeutics (1) · The Affiliated Hospital of Qingdao University (1) · The Netherlands Cancer Institute (1)
China (2) · France (1) · Netherlands (1) · South Korea (1)
Dong-Ho Nahm (1) · Lotje Zuur, MD, PhD (1)